| Symbol | BCDA |
|---|---|
| Name | BIOCARDIA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 320 SOQUEL WAY, SUNNYVALE, California, 94085, United States |
| Telephone | +1 650 226-0120 |
| Fax | — |
| — | |
| Website | https://www.biocardia.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000925741 |
| Description | BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus on heart failure resulting from a heart attack. Additional info from NASDAQ: |
Director Altman Peter 🟢 acquired 4.3K shares of BioCardia, Inc. (BCDA) at $0.88 Transaction Date: Jul 14, 2026 | Filing ID: 023637
Read moreDirector Altman Peter 🟢 acquired 5.4K shares of BioCardia, Inc. (BCDA) at $0.96 Transaction Date: Jul 08, 2026 | Filing ID: 023016
Read moreDirector STERTZER SIMON H 🟢 acquired 8.0K shares (1 derivative) of BioCardia, Inc. (BCDA) at $1.20 Transaction Date: Jul 06, 2026 | Filing ID: 022970
Read moreDirector Slosman Marvin 🟢 acquired 8.0K shares (1 derivative) of BioCardia, Inc. (BCDA) at $1.20 Transaction Date: Jul 06, 2026 | Filing ID: 022965
Read moreDirector Altman Peter 🟡 adjusted position in 3.1K shares (1 derivative) of BioCardia, Inc. (BCDA) at $1.24 Transaction Date: Jul 02, 2026 | Filing ID: 022969
Read moreMcClung David 🟡 adjusted position in 18.4K shares (1 derivative) of BioCardia, Inc. (BCDA) at $1.24 Transaction Date: Jul 02, 2026 | Filing ID: 022968
Read moreGILLIS EDWARD M 🟡 adjusted position in 12.2K shares (1 derivative) of BioCardia, Inc. (BCDA) at $1.24 Transaction Date: Jul 02, 2026 | Filing ID: 022967
Read moreDirector Blank Andrew Scott 🟢 acquired 8.0K shares (1 derivative) of BioCardia, Inc. (BCDA) at $1.20 Transaction Date: Jul 06, 2026 | Filing ID: 022966
Read moreDirector Allen Jim L. 🟢 acquired 8.0K shares (1 derivative) of BioCardia, Inc. (BCDA) at $1.20 Transaction Date: Jul 06, 2026 | Filing ID: 022964
Read moreDirector MOYES JAY M 🟢 acquired 8.0K shares (1 derivative) of BioCardia, Inc. (BCDA) at $1.20 Transaction Date: Jul 06, 2026 | Filing ID: 022963
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05491681 | AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acut… | Phase1 | ARDS, Human | Withdrawn | 2026-01-04 | 2026-01-04 | ClinicalTrials.gov |
| NCT06258447 | CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With R… | Na | Ischemic Heart Failure | Recruiting | 2024-08-01 | 2029-04-01 | ClinicalTrials.gov |
| NCT05925608 | Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchy… | Phase1 | Heart Failure, Systolic | Active_Not_Recruiting | 2023-08-23 | 2027-12-01 | ClinicalTrials.gov |
| NCT03455725 | CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial | Na | Refractory Angina | Active_Not_Recruiting | 2021-06-30 | 2027-12-01 | ClinicalTrials.gov |
| NCT02438306 | CardiAMP™ Cell Therapy for Heart Failure Trial | Phase3 | Heart Failure, Systolic | Completed | 2016-12-01 | 2025-06-01 | ClinicalTrials.gov |
| NCT00507468 | Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic My… | Phase1 | Ventricular Dysfunction | Completed | 2005-12-01 | 2009-08-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Sham | Other | Phase PHASE3 | Heart Failure, Systolic | COMPLETED | NCT02438306 |
| Autologous cell therapy | Drug | Phase PHASE3 | Heart Failure, Systolic | COMPLETED | NCT02438306 |
| Diagnostic Catheterization | Other | Phase PHASE1 | Heart Failure, Systolic | ACTIVE_NOT_RECRUITING | NCT05925608 |
| CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs) | Other | Phase PHASE1 | Heart Failure, Systolic | ACTIVE_NOT_RECRUITING | NCT05925608 |
| Sham Treatment | Drug | Approved | Refractory Angina | ACTIVE_NOT_RECRUITING | NCT03455725 |
| CardiAMP Cell Therapy System | Drug | Approved | Refractory Angina | ACTIVE_NOT_RECRUITING | NCT03455725 |
| intravenous delivery of allogeneic bone marrow-derived MSCs | Other | Phase PHASE1 | ARDS, Human | WITHDRAWN | NCT05491681 |
| Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system | Drug | Approved | Ischemic Heart Failure | RECRUITING | NCT06258447 |
| Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system | DEVICE | Approved | Ischemic Heart Failure | RECRUITING | NCT06258447 |
| intravenous delivery of allogeneic bone marrow-derived MSCs | BIOLOGICAL | Phase PHASE1 | ARDS, Human | WITHDRAWN | NCT05491681 |
| Sham Treatment | OTHER | Approved | Refractory Angina | ACTIVE_NOT_RECRUITING | NCT03455725 |
| CardiAMP Cell Therapy System | DEVICE | Approved | Refractory Angina | ACTIVE_NOT_RECRUITING | NCT03455725 |
| Sham | OTHER | Phase PHASE3 | Heart Failure, Systolic | COMPLETED | NCT02438306 |
| Autologous cell therapy | BIOLOGICAL | Phase PHASE3 | Heart Failure, Systolic | COMPLETED | NCT02438306 |
| Transendocaridal Transplantation of Autologous Bone Marrow | PROCEDURE | Phase PHASE1 | Ventricular Dysfunction | COMPLETED | NCT00507468 |